A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.
Matthew S. Davids(Dana-Farber Cancer Institute), Philip A. Thompson(The Royal Melbourne Hospital), Josie Montegaard(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Kerry A. Rogers(The Ohio State University), Michael A. Rocchio(Dana-Farber Cancer Institute), Samantha Pazienza(Dana-Farber Cancer Institute), Sarah Renner(The University of Texas MD Anderson Cancer Center), Udochukwu Ihuoma(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752